​

Funding Round

Series A - Cajal Neuroscience

Series A - Cajal Neuroscience

Investment Firm

Overview

Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.

Announced Date

Nov 29, 2022

Funding Type

Series A

Highlights

Location

United States, North America

Social

Investor Lead

The Column Group

The Column Group

The Column Group is a early_stage_venture and late_stage_venture and post_ipo and private_equity and seed firm.

Lux Capital

Lux Capital

Lux Capital is a debt and early_stage_venture and late_stage_venture and private_equity and seed and venture firm.

Participant Investors

7

Investor Name
Participant InvestorLux Capital
Participant InvestorBristol-Myers Squibb
Participant InvestorThe Column Group
Participant InvestorTwo Sigma Ventures
Participant InvestorDolby Family Ventures

Round Details and Background

Cajal Neuroscience raised $96000000 on 2022-11-29 in Series A

Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.

Company Funding History

2

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jan 01, 2020
Seed Round - Cajal Neuroscience
1-undefined
Nov 29, 2022
Series A - Cajal Neuroscience
7-96.0M

Recent Activity

There is no recent news or activity for this profile.